vericiguat Side Effects
Also known as: Verquvo
Analysis of 905 adverse event reports submitted to the FDA from 2017 to 2025.
Total Reports
905
Death-Related
135
14.9% of reports
Hospitalizations
215
23.8% of reports
Top Indication
Cardiac Failure
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 135 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 89 |
| CARDIAC FAILURE | 19 |
| ILL-DEFINED DISORDER | 8 |
| CARDIAC ARREST | 7 |
| ADVERSE EVENT | 6 |
| CARDIAC DISORDER | 5 |
| PNEUMONIA | 5 |
| ILLNESS | 4 |
| TREATMENT NONCOMPLIANCE | 4 |
| ATRIAL FIBRILLATION | 3 |
| BLOOD PRESSURE DECREASED | 3 |
| BRAIN NATRIURETIC PEPTIDE INCREASED | 3 |
| CHRONIC KIDNEY DISEASE | 3 |
| EJECTION FRACTION DECREASED | 3 |
| HOSPICE CARE | 3 |
| INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION | 3 |
| MALAISE | 3 |
| MYOCARDIAL INFARCTION | 3 |
| NAUSEA | 3 |
| RENAL FAILURE | 3 |
Reactions in Hospitalization Reports
Top reactions in 215 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| CARDIAC FAILURE | 36 |
| HYPOTENSION | 24 |
| HOSPITALISATION | 19 |
| ANAEMIA | 16 |
| DEATH | 16 |
| ADVERSE EVENT | 13 |
| DYSPNOEA | 12 |
| ASTHENIA | 9 |
| DIZZINESS | 8 |
| OEDEMA PERIPHERAL | 8 |
| ATRIAL FIBRILLATION | 7 |
| BLOOD PRESSURE DECREASED | 7 |
| PNEUMONIA | 7 |
| ACUTE KIDNEY INJURY | 6 |
| CARDIAC FAILURE CHRONIC | 6 |
| GASTROINTESTINAL HAEMORRHAGE | 6 |
| MALAISE | 6 |
| RENAL IMPAIRMENT | 6 |
| CARDIAC DISORDER | 5 |
| DYSPNOEA EXERTIONAL | 5 |
Nearby — Related Medications
What the FAERS Data Reveals About vericiguat Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 905 voluntary reports linked to vericiguat and its brand equivalents (Verquvo), spanning 2017 through 2025. Of those, 135 (14.9%) listed death as an outcome and 215 (23.8%) involved hospitalization. The most common indication reported alongside adverse events was Cardiac Failure.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 34% were female and 66% male; age distribution skews toward 75+, with 181 reports in that bracket. The single most reported reaction is hypotension with 106 submissions, followed by death and dizziness.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.